Table 2.
Standardized incidence ratios of subsequent cancer among 2-month female survivors of first primary breast-ACC
| Subsequent cancera | Obs. | SIR | 95% CI |
|---|---|---|---|
| All cancers, excluding nonmelanoma skin | 40 | 1.01 | 0.72 to 1.38 |
| All solid cancers | 33 | 0.94 | 0.65 to 1.32 |
| Colon and rectum | 8 | 1.43 | 0.62 to 2.81 |
| Lung and bronchus | 7 | 1.24 | 0.50 to 2.55 |
| Female breast | 10 | 0.89 | 0.43 to 1.64 |
| Uterine corpus | 3 | 1.27 | 0.26 to 3.72 |
| All lymphohematopoietic cancers | 6 | 1.86 | 0.68 to 4.05 |
| Non-Hodgkin lymphoma | 4 | 2.44 | 0.66 to 6.24 |
| Acute myeloid leukemia | 2 | 7.24 | 0.88 to 26.16 |
Data from the nine cancer registry areas of the Surveillance, Epidemiology and End Results Program, 1977 to 2006. Breast-ACC, adenoid cystic carcinoma of the breast; Obs., observed number of subsequent cancers; SIR, standardized incidence ratio; CI, confidence interval. aLimited to cancer sites with >1 case diagnosed among 300 2-month survivors (2,986 female-years; mean follow-up 9.95 years) of first primary breast-ACC. There was one individual with miscellaneous cancer that is not included in the all solid cancers or all lymphohematopoietic cancers categories.